Abstract library

246 results for "inhibitor screening".
#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
Authors: Armstrong L, Ryan K, Ardill J, ...
#815 The Effect of Autophagy Inhibitors Alone or in Combination with mTOR Inhibitors in a Neuroendocrine Tumor Cell Model
Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Simona Glasberg
#1306 The Role of Ga68-DOTATOC-PET-CT in Routine Screening of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 is a tumor syndrome characterized by NENs of the pancreas, duodenum, parathyroid, pituitary, adrenal, thymus and bronchi. Gene carriers are recommended participation in prospective screening programs at expert centers. Ga68-DOTATOC-PET-CT is an increasingly used very sensitive imaging technique for GEP-NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Max Benjamin Albers
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MASTER DEGREE Katiuscia Benfini
#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?
Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
Keywords: Screening, MEN1
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#430 mTOR Inhibitors Hamper Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that mTOR inhibitors have potent anti-proliferative effects in a human Medullary Thyroid Carcinoma (MTC) cell line. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3K pathway) on the effects of Insulin-like Growth Factor-1 (IGF-1) in human MTC primary cultures.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mrs. Mariella Minoia
#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#1221 Pancreatic Location, High Proliferation and Low p-mTOR Expression Levels Are More Frequent in Neuroendocrine Tumor Patients Responsive to mTOR Inhibitors: Results from a Preliminary Study
Introduction: MTOR inhibitors are approved for the treatment of advanced neuroendocrine tumors. However, scarce data are available on clinical or pathological predictors of response to these agents
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Marco Volante
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.